Different Effects of Resveratrol on Dose-related Doxorubicin-induced Heart and Liver Toxicity

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2012 Dec 22

PMID 23258992

Citations 25

Authors

Jaroslaw Dudka

Renata Gieroba

Agnieszka Korga

Franciszek Burdan

Wlodzimierz Matysiak

Barbara Jodlowska-Jedrych

Slawomir Mandziuk

Elzbieta Korobowicz

Marek Murias

Affiliations

Soon will be listed here.

Abstract

The aim of the study was to evaluate the effect of resveratrol in doxorubicin-induced cardiac and hepatic toxicity. Doxorubicin was administered once a week throughout the period of 7 weeks with 1.0 or 2.0 mg/kg body weight or concomitantly with resveratrol (20 mg/kg of feed). Heart and liver toxicity was histologically and biochemically evaluated. Resveratrol protected from the heart lipid peroxidation caused by 1 mg doxorubicin and it sharply diminished superoxide dismutase activity. An insignificant effect of resveratrol on the lipid peroxidation level and the superoxide dismutase activity was observed in the hearts of rats administered a higher dose of doxorubicin. However, resveratrol attenuate necrosis and other cardiac histopathological changes were induced by a high dose of doxorubicin. Interestingly, it slightly intensified adverse cardiac histological changes in rats receiving a lower dose of doxorubicin. Resveratrol did not have any protective effect on the hepatic oxidative stress, while exerting a mild beneficial effect on the morphological changes caused by doxorubicin. All in all, this study has shown different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Resveratrol may modulate the hepatic and cardiac effect of doxorubicin, depending on the drug dose.

Citing Articles

Doxorubicin-Induced Cardiac Remodeling: Mechanisms and Mitigation Strategies.

Sun Y, Xiao L, Chen L, Wang X Cardiovasc Drugs Ther. 2025; .

PMID: 40009315 DOI: 10.1007/s10557-025-07673-6.

A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity.

Singh M, Kadhim M, Turki Jalil A, Oudah S, Aminov Z, Alsaikhan F Cancer Cell Int. 2023; 23(1):88.

PMID: 37165384 PMC: 10173635. DOI: 10.1186/s12935-023-02936-4.

mechanisms of arsenic trioxide-induced cardiotoxicity.

Li Y, Wan R, Liu J, Liu W, Ma L, Zhang H Front Physiol. 2023; 13:1004605.

PMID: 36589437 PMC: 9798418. DOI: 10.3389/fphys.2022.1004605.

Activation of SIRT-1 Pathway by Nanoceria Sheds Light on Its Ameliorative Effect on Doxorubicin-Induced Cognitive Impairment (Chemobrain): Restraining Its Neuroinflammation, Synaptic Dysplasticity and Apoptosis.

Taha M, Elazab S, Badawy A, Saati A, Qusty N, Al-Kushi A Pharmaceuticals (Basel). 2022; 15(8).

PMID: 35893742 PMC: 9394293. DOI: 10.3390/ph15080918.

In Vitro and In Vivo Cardioprotective Effects of Curcumin against Doxorubicin-Induced Cardiotoxicity: A Systematic Review.

Zhang Q, Wu L J Oncol. 2022; 2022:7277562.

PMID: 35237323 PMC: 8885194. DOI: 10.1155/2022/7277562.

References

Sener G, Topaloglu N, Sehirli A, Ercan F, Gedik N . Resveratrol alleviates bleomycin-induced lung injury in rats. Pulm Pharmacol Ther. 2006; 20(6):642-9. DOI: 10.1016/j.pupt.2006.07.003. View

Ungvari Z, Bagi Z, Feher A, Recchia F, Sonntag W, Pearson K . Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol. 2010; 299(1):H18-24. PMC: 2904129. DOI: 10.1152/ajpheart.00260.2010. View

Berthiaume J, Wallace K . Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2006; 23(1):15-25. DOI: 10.1007/s10565-006-0140-y. View

Aggarwal B, Bhardwaj A, Aggarwal R, Seeram N, Shishodia S, Takada Y . Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004; 24(5A):2783-840. View

Yee S, Pritsos C . Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase. Arch Biochem Biophys. 1997; 347(2):235-41. DOI: 10.1006/abbi.1997.0340. View

Chen Y, Saari J, Kang Y . Weak antioxidant defenses make the heart a target for damage in copper-deficient rats. Free Radic Biol Med. 1994; 17(6):529-36. DOI: 10.1016/0891-5849(94)90092-2. View

Fulbright J . Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiol Res Pract. 2011; 2011:942090. PMC: 3102324. DOI: 10.4061/2011/942090. View

Johnson B, Cheang M, GOLDENBERG G . Comparison of adriamycin uptake in chick embryo heart and liver cells an murine L5178Y lymphoblasts in vitro: role of drug uptake in cardiotoxicity. Cancer Res. 1986; 46(1):218-23. View

Lebrecht D, Geist A, Ketelsen U, Haberstroh J, Setzer B, Walker U . Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol. 2007; 151(6):771-8. PMC: 2014121. DOI: 10.1038/sj.bjp.0707294. View

10.

Roy S, Sannigrahi S, Majumdar S, Ghosh B, Sarkar B . Resveratrol regulates antioxidant status, inhibits cytokine expression and restricts apoptosis in carbon tetrachloride induced rat hepatic injury. Oxid Med Cell Longev. 2011; 2011:703676. PMC: 3195554. DOI: 10.1155/2011/703676. View

11.

Mansour M, El-Din A, Nagi M, Al-Shabanah O, Al-Bekairi A . Nomega-nitro-L-arginine methylester ameliorates myocardial toxicity induced by doxorubicin. J Biochem Mol Biol. 2003; 36(6):593-6. DOI: 10.5483/bmbrep.2003.36.6.593. View

12.

Korga A, Dudka J, Burdan F, Sliwinska J, Mandziuk S, Dawidek-Pietryka K . The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin. Oxid Med Cell Longev. 2012; 2012:681367. PMC: 3317061. DOI: 10.1155/2012/681367. View

13.

Luther D, Ohanyan V, Shamhart P, Hodnichak C, Sisakian H, Booth T . Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. Invest New Drugs. 2009; 29(2):380-91. DOI: 10.1007/s10637-009-9332-7. View

14.

Al-Abd A, Mahmoud A, El-Sherbiny G, El-Moselhy M, Nofal S, El-Latif H . Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif. 2011; 44(6):591-601. PMC: 6496784. DOI: 10.1111/j.1365-2184.2011.00783.x. View

15.

Al-Shabanah O, Aleisa A, Hafez M, Al-Rejaie S, Al-Yahya A, Bakheet S . Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-β/Smad p53 pathway in rat model. Oxid Med Cell Longev. 2012; 2012:619185. PMC: 3350848. DOI: 10.1155/2012/619185. View

16.

Danz E, Skramsted J, Henry N, Bennett J, Keller R . Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med. 2009; 46(12):1589-97. DOI: 10.1016/j.freeradbiomed.2009.03.011. View

17.

Dudka J, Jodynis-Liebert J, Korobowicz E, Burdan F, Korobowicz A, Szumilo J . Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: an in vitro study. Basic Clin Pharmacol Toxicol. 2005; 97(2):74-9. DOI: 10.1111/j.1742-7843.2005.pto_98.x. View

18.

Dudka J, Burdan F, Korga A, Dyndor K, Syroka I, Zieba J . [The diagnosis of anthracycline-induced cardiac damage and heart failure]. Postepy Hig Med Dosw (Online). 2009; 63:225-33. View

19.

Wang G, Wang Y, Zhang L, Li Q, Yue H, Song C . [Effect of resveratrol on heart function of rats with adriamycin-induced heart failure]. Zhongguo Zhong Yao Za Zhi. 2007; 32(15):1563-5. View

20.

Crowell J, Korytko P, Morrissey R, Booth T, Levine B . Resveratrol-associated renal toxicity. Toxicol Sci. 2004; 82(2):614-9. DOI: 10.1093/toxsci/kfh263. View